Report #2834469

Overview

Sex

Female

Age

Age unknown

State

PA

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

A patient received a dose of Priorix via Intramuscular instead of subcutaneous injection; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a female patient who received MMR (Priorix) (batch number 4N222, expiry date 13-SEP-2026) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: A patient received a dose of Priorix via Intramuscular instead of subcutaneous injection). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-MAR-2025 A pharmacist reported that a female patient received Priorix intramuscularly instead of subcutaneously which led to subcutaneous injection formulation administered by other route. The reporter wanted to know if it was going to be harmful for the patient.